Skip to main content
. 2019 Sep 3;2019:4782730. doi: 10.1155/2019/4782730

Figure 1.

Figure 1

KIF20A expression in prostate cancer and biochemical recurrence- (BCR-) free survival for PCa patients according to the KIF20A expression. (a) The expression of KIF20A at the mRNA level in 7 PCa patients by qPCR. (b) The expression of KIF20A at the protein level in 7 PCa patients by Western blotting. (c) Immunoreactive KIF20A expression in 114 PCa patients (tumor vs. paracancerous tissues; paraffin section). (d) BCR-free survival in PCa patients according to the KIF20A expression from the TCGA dataset. Blue line indicates low KIF20A expression (n = 298). Red line indicates high KIF20A expression (n = 298). Patients with high KIF20A expression showed significantly poorer BCR-free survival. Data represent mean ± SD. ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001.